Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark F Brady

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
The New England Journal of Medicine|November 14, 2019
Secondary Surgical Cytoreduction for Recurrent Ovarian CancerRobert L Coleman, Nick M Spirtos, Danielle Enserro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian CancerKrishnansu S Tewari, Robert A Burger, Danielle Enserro, et al.
The New England Journal of Medicine|September 29, 2019
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian CancerRobert L Coleman, Gini F Fleming, Mark F Brady, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
The New England Journal of Medicine|November 14, 2019
Secondary Surgical Cytoreduction for Recurrent Ovarian CancerRobert L Coleman, Nick M Spirtos, Danielle Enserro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian CancerKrishnansu S Tewari, Robert A Burger, Danielle Enserro, et al.
The New England Journal of Medicine|September 29, 2019
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian CancerRobert L Coleman, Gini F Fleming, Mark F Brady, et al.
Pageof 7